Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Transkaryotic Therapies in $66.5mm licensing deal with HMR

Executive Summary

Transkaryotic Therapies (gene therapy) will license an undisclosed Gene Activation protein (possibly G-CSF) to Hoechst Marion Roussel for (uf)$20mm up front ($10mm licensing fee and $10mm equity). TKT will get $4.5mm in research (but TKT's 8/96 S-1 filing says that's $3mm a year for two years), $42mm in milestones, and estimated 12% royalties.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies